AGIO Quote, Financials, Valuation and Earnings

Arvinas has a net margin of -1023.25% compared to Agios Pharmaceuticals's net margin of 43.91%. Agios Pharmaceuticals's return on equity of 55.14% beat Arvinas's return on equity of -7.72%.

Agios Pharmaceuticals has a consensus price target of $52.43, signalling upside risk potential of 91.91%. On the other hand Arvinas has an analysts' consensus of $22.36 which suggests that it could grow by 238.29%. Given that Arvinas has higher upside potential than Agios Pharmaceuticals, analysts believe Arvinas is more attractive than Agios Pharmaceuticals.

Agios Pharmaceuticals has a beta of 0.774, which suggesting that the stock is 22.618% less volatile than S&P 500. In comparison Arvinas has a beta of 2.215, suggesting its more volatile than the S&P 500 by 121.499%.

Agios Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arvinas offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agios Pharmaceuticals pays -- of its earnings as a dividend. Arvinas pays out -- of its earnings as a dividend.

Agios Pharmaceuticals quarterly revenues are $8.7M, which are smaller than Arvinas quarterly revenues of $188.8M. Agios Pharmaceuticals's net income of -$89.3M is lower than Arvinas's net income of $82.9M. Notably, Agios Pharmaceuticals's price-to-earnings ratio is 2.43x while Arvinas's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agios Pharmaceuticals is 42.69x versus 1.12x for Arvinas. Usually stocks with elevated PS ratios are considered overvalued.

Blueprint Medicines has a net margin of -1023.25% compared to Agios Pharmaceuticals's net margin of 0.33%. Agios Pharmaceuticals's return on equity of 55.14% beat Blueprint Medicines's return on equity of -49.13%.

Agios Pharmaceuticals has a consensus price target of $52.43, signalling upside risk potential of 91.91%. On the other hand Blueprint Medicines has an analysts' consensus of $126.10 which suggests that it could grow by 29.77%. Given that Agios Pharmaceuticals has higher upside potential than Blueprint Medicines, analysts believe Agios Pharmaceuticals is more attractive than Blueprint Medicines.

Agios Pharmaceuticals has a beta of 0.774, which suggesting that the stock is 22.618% less volatile than S&P 500. In comparison Blueprint Medicines has a beta of 0.829, suggesting its less volatile than the S&P 500 by 17.117%.

Agios Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Blueprint Medicines offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agios Pharmaceuticals pays -- of its earnings as a dividend. Blueprint Medicines pays out -- of its earnings as a dividend.

Agios Pharmaceuticals quarterly revenues are $8.7M, which are smaller than Blueprint Medicines quarterly revenues of $149.4M. Agios Pharmaceuticals's net income of -$89.3M is lower than Blueprint Medicines's net income of $496K. Notably, Agios Pharmaceuticals's price-to-earnings ratio is 2.43x while Blueprint Medicines's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agios Pharmaceuticals is 42.69x versus 11.08x for Blueprint Medicines. Usually stocks with elevated PS ratios are considered overvalued.

Amicus Therapeutics has a net margin of -1023.25% compared to Agios Pharmaceuticals's net margin of -17.31%. Agios Pharmaceuticals's return on equity of 55.14% beat Amicus Therapeutics's return on equity of -17.7%.

Agios Pharmaceuticals has a consensus price target of $52.43, signalling upside risk potential of 91.91%. On the other hand Amicus Therapeutics has an analysts' consensus of $15.82 which suggests that it could grow by 164.52%. Given that Amicus Therapeutics has higher upside potential than Agios Pharmaceuticals, analysts believe Amicus Therapeutics is more attractive than Agios Pharmaceuticals.

Agios Pharmaceuticals has a beta of 0.774, which suggesting that the stock is 22.618% less volatile than S&P 500. In comparison Amicus Therapeutics has a beta of 0.640, suggesting its less volatile than the S&P 500 by 35.979%.

Agios Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agios Pharmaceuticals pays -- of its earnings as a dividend. Amicus Therapeutics pays out -- of its earnings as a dividend.

Agios Pharmaceuticals quarterly revenues are $8.7M, which are smaller than Amicus Therapeutics quarterly revenues of $125.2M. Agios Pharmaceuticals's net income of -$89.3M is lower than Amicus Therapeutics's net income of -$21.7M. Notably, Agios Pharmaceuticals's price-to-earnings ratio is 2.43x while Amicus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agios Pharmaceuticals is 42.69x versus 3.36x for Amicus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Sage Therapeutics has a net margin of -1023.25% compared to Agios Pharmaceuticals's net margin of -442.4%. Agios Pharmaceuticals's return on equity of 55.14% beat Sage Therapeutics's return on equity of -64.19%.

Agios Pharmaceuticals has a consensus price target of $52.43, signalling upside risk potential of 91.91%. On the other hand Sage Therapeutics has an analysts' consensus of $8.21 which suggests that it could grow by 25.2%. Given that Agios Pharmaceuticals has higher upside potential than Sage Therapeutics, analysts believe Agios Pharmaceuticals is more attractive than Sage Therapeutics.

Agios Pharmaceuticals has a beta of 0.774, which suggesting that the stock is 22.618% less volatile than S&P 500. In comparison Sage Therapeutics has a beta of 0.205, suggesting its less volatile than the S&P 500 by 79.546%.

Agios Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sage Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agios Pharmaceuticals pays -- of its earnings as a dividend. Sage Therapeutics pays out -- of its earnings as a dividend.

Agios Pharmaceuticals quarterly revenues are $8.7M, which are smaller than Sage Therapeutics quarterly revenues of $14.1M. Agios Pharmaceuticals's net income of -$89.3M is lower than Sage Therapeutics's net income of -$62.2M. Notably, Agios Pharmaceuticals's price-to-earnings ratio is 2.43x while Sage Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agios Pharmaceuticals is 42.69x versus 8.47x for Sage Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.